TL;DR — Nattokinase is a fibrinolytic enzyme from fermented soybean (natto). A meta-analysis of RCTs shows it modestly lowers systolic and diastolic blood pressure, and trials show favorable effects on fibrinolysis markers. Genuinely useful for cardiovascular support — but it thins the blood, so it's the one on this list with a real interaction to respect. 100 mg (~2,000 FU)/day.
What nattokinase does (and why it matters)
Aging blood gets more thrombotic and stiffer, and blood pressure creeps up. Nattokinase acts on both fronts: it directly degrades fibrin (the protein scaffold of clots), enhances the body's own clot-dissolving system, and lowers blood pressure in controlled trials. That combination — mild antihypertensive plus profibrinolytic — is unusual for a supplement.
Primary hallmarks targeted: Altered intercellular communication · Chronic inflammation
Mechanism — direct fibrinolysis plus blood-pressure lowering
Nattokinase is a serine protease (subtilisin NAT) that cleaves fibrin directly and boosts endogenous fibrinolysis (raising plasmin activity and reducing markers like von Willebrand factor). Blood-pressure lowering appears to involve reduced angiotensin-converting-enzyme activity and improved vascular tone. The net effect is less thrombotic tendency and modestly lower pressure.
Evidence summary
| Study | Design | N | Duration | Key outcome | Tier |
|---|---|---|---|---|---|
| Li 2023 (PMID 39076715) | Meta-analysis (6 RCTs) | 546 | — | SBP −3.45 / DBP −2.32 mmHg; lipid effects mixed; slight glucose rise | B |
| Jensen 2016 (PMID 27785095) | RCT, double-blind | 79 | 8 wk | 100 mg/d lowered BP and von Willebrand factor (N. American cohort) | B |
← Swipe for more columns →
Consensus: Across trials nattokinase reliably nudges blood pressure down and improves fibrinolytic markers, and it now has data outside the original Asian cohorts. The lipid effects are inconsistent (dose-dependent and sometimes unfavorable), and there are no hard-outcome trials — so the defensible story is BP plus fibrinolysis, not cholesterol.
Where nattokinase disappoints
- Lipids — the meta-analysis found mixed, dose-dependent effects; don't take it for cholesterol. - Hard outcomes — no stroke/heart-attack prevention trials exist; the case rests on surrogates. - "More is better" — higher total doses looked worse for some lipid markers; this isn't a dose-to-effect lever.
What would change this grade. The tier is B because a clean meta-analysis supports the BP and fibrinolysis effects, but there are no clinical-outcome trials. It would rise with event data; it would fall if larger trials failed to reproduce the BP effect.
Dosing protocol
| Parameter | Recommendation | Notes |
|---|---|---|
| Dose | 100 mg (~2,000 FU)/day | Trials used ~100 mg; "FU" measures enzyme activity |
| Timing | Away from meals | An empty stomach favors enzyme activity |
| Form | Vitamin-K2-reduced (e.g. NSK-SD) if on warfarin considerations | Natto is naturally K2-rich |
Monitoring
Home blood pressure over 4–8 weeks. If you are on any antithrombotic therapy, your clinician may want to watch for bruising/bleeding rather than a specific lab.
Safety, red flags, and contraindications
- The key caution on this list — nattokinase is fibrinolytic; it meaningfully affects clotting.
Do not self-start without clearance
- Anticoagulants / antiplatelets (warfarin, DOACs, aspirin, clopidogrel) — additive bleeding risk; requires physician oversight.
- Bleeding disorders or upcoming surgery — stop well in advance; clear with your surgeon.
- Recent stroke or active bleeding — avoid.
Who should skip nattokinase
- Anyone on blood thinners without explicit medical supervision. - People with bleeding disorders. - Those taking it for cholesterol — the lipid data don't support that use.
Synergies and antagonists
Pairs well with:
| Partner | Rationale | Guide |
|---|---|---|
| Beetroot nitrate | Complementary blood-pressure mechanism | Cardiovascular stack |
| Aged garlic | Adds NO/H₂S BP support (mind the combined antiplatelet load) | Cardiovascular stack |
| Omega-3 | Broader cardiovascular support | Cardiovascular stack |
Works against / redundant with: The important interaction is additive, not antagonistic — stacking nattokinase with other blood-thinning agents (fish oil, high-dose garlic, aspirin) compounds bleeding risk. Coordinate the whole antithrombotic load with a clinician rather than adding piecemeal.
Personal results template
My nattokinase results log
| Date | Week | Dose | Home SBP | Home DBP | Notes |
|---|---|---|---|---|---|
| YYYY-MM-DD | 0 | — | — | — | Baseline |
| YYYY-MM-DD | 8 | — | — | — | Endpoint |
← Swipe for more columns →
Response criteria (personal, not clinical): - Meaningful: a consistent home-BP reduction - Plateau: no BP change by 8 weeks → reassess - Adverse: any unusual bruising/bleeding → stop and call your clinician
References
Links open PubMed. TNiC does not sell supplements; citations support education, not medical advice.